Trends in inpatient antiparkinson drug use in the USA, 2001-2012

Autores
Crispo, James; Fortin, Yannick; Thibault, Dylan P.; Emons, Matthew; Bjerre, Lise M.; Kohen, Dafna E.; Pérez Lloret, Santiago; Mattison, Donald; Willis, Allison W.; Krewski, Daniel
Año de publicación
2015
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Purpose: Although therapeutic options and clinical guidelines for Parkinson's disease (PD) have changed significantly in the past 15 years, prescribing trends in the USA remain unknown. The purpose of this population-based cohort study was to examine patterns of inpatient antiparkinson drug use between January 2001 and December 2012 in relation to clinical guideline publication, drug introduction/withdrawal, and emerging safety concerns. Methods: A total of 16,785 inpatients receiving pharmacological treatment for PD were identified in the Cerner Health Facts database. Our primary outcome was standardized (age, sex, race, and census region) annual prevalence of antiparkinson drug use. We also examined antiparkinson medication trends and polypharmacy by age and sex. Results: The most frequently prescribed antiparkinson drugs between 2001 and 2012 were levodopa (85 %) and dopamine agonists (28 %). Dopamine agonist use began declining in 2007, from 34 to 27 % in 2012. The decline followed publication of the American Academy of Neurology's practice parameter refuting levodopa toxicity, pergolide withdrawal, and pramipexole label revisions. Despite safety concerns for cognitive impairment and falls, individuals = 80 years of age demonstrated stable rates of dopamine agonist use from 2001 to 2012. Polypharmacy was most common in younger patients. Conclusions: Dopamine agonist use declined from 2007 to 2012, suggesting that increased awareness of safety issues and practice guidelines influenced prescribing. These events appear to have minimally influenced treatment provided to older PD patients. Antiparkinson prescribing trends indicate that safety and best practice information may be communicated effectively.
Fil: Crispo, James. University of Ottawa; Canadá. University of Pennsylvania; Estados Unidos
Fil: Fortin, Yannick. University of Ottawa; Canadá
Fil: Thibault, Dylan P.. University of Pennsylvania; Estados Unidos
Fil: Emons, Matthew. Cerner Corporation; Estados Unidos
Fil: Bjerre, Lise M.. University of Ottawa; Canadá. Bruyère Research Institute; Canadá
Fil: Kohen, Dafna E.. University of Ottawa; Canadá
Fil: Pérez Lloret, Santiago. Pontificia Universidad Católica Argentina "Santa María de los Buenos Aires"; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Mattison, Donald. Risk Sciences International; Canadá. University of Ottawa; Canadá
Fil: Willis, Allison W.. University of Pennsylvania; Estados Unidos
Fil: Krewski, Daniel. University of Ottawa; Canadá
Materia
Cohort Study
Drug Utilization
Medical Records
Parkinson'S Disease
Pharmacoepidemiology
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/38806
Acceder
id CONICETDig_9f6245ef78c12ed107ea494335cc8b50
oai_identifier_str oai:ri.conicet.gov.ar:11336/38806
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Trends in inpatient antiparkinson drug use in the USA, 2001-2012Crispo, JamesFortin, YannickThibault, Dylan P.Emons, MatthewBjerre, Lise M.Kohen, Dafna E.Pérez Lloret, SantiagoMattison, DonaldWillis, Allison W.Krewski, DanielCohort StudyDrug UtilizationMedical RecordsParkinson'S DiseasePharmacoepidemiologyhttps://purl.org/becyt/ford/3.2https://purl.org/becyt/ford/3Purpose: Although therapeutic options and clinical guidelines for Parkinson's disease (PD) have changed significantly in the past 15 years, prescribing trends in the USA remain unknown. The purpose of this population-based cohort study was to examine patterns of inpatient antiparkinson drug use between January 2001 and December 2012 in relation to clinical guideline publication, drug introduction/withdrawal, and emerging safety concerns. Methods: A total of 16,785 inpatients receiving pharmacological treatment for PD were identified in the Cerner Health Facts database. Our primary outcome was standardized (age, sex, race, and census region) annual prevalence of antiparkinson drug use. We also examined antiparkinson medication trends and polypharmacy by age and sex. Results: The most frequently prescribed antiparkinson drugs between 2001 and 2012 were levodopa (85 %) and dopamine agonists (28 %). Dopamine agonist use began declining in 2007, from 34 to 27 % in 2012. The decline followed publication of the American Academy of Neurology's practice parameter refuting levodopa toxicity, pergolide withdrawal, and pramipexole label revisions. Despite safety concerns for cognitive impairment and falls, individuals = 80 years of age demonstrated stable rates of dopamine agonist use from 2001 to 2012. Polypharmacy was most common in younger patients. Conclusions: Dopamine agonist use declined from 2007 to 2012, suggesting that increased awareness of safety issues and practice guidelines influenced prescribing. These events appear to have minimally influenced treatment provided to older PD patients. Antiparkinson prescribing trends indicate that safety and best practice information may be communicated effectively.Fil: Crispo, James. University of Ottawa; Canadá. University of Pennsylvania; Estados UnidosFil: Fortin, Yannick. University of Ottawa; CanadáFil: Thibault, Dylan P.. University of Pennsylvania; Estados UnidosFil: Emons, Matthew. Cerner Corporation; Estados UnidosFil: Bjerre, Lise M.. University of Ottawa; Canadá. Bruyère Research Institute; CanadáFil: Kohen, Dafna E.. University of Ottawa; CanadáFil: Pérez Lloret, Santiago. Pontificia Universidad Católica Argentina "Santa María de los Buenos Aires"; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Mattison, Donald. Risk Sciences International; Canadá. University of Ottawa; CanadáFil: Willis, Allison W.. University of Pennsylvania; Estados UnidosFil: Krewski, Daniel. University of Ottawa; CanadáSpringer2015-08info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/38806Crispo, James; Fortin, Yannick; Thibault, Dylan P.; Emons, Matthew; Bjerre, Lise M.; et al.; Trends in inpatient antiparkinson drug use in the USA, 2001-2012; Springer; European Journal Of Clinical Pharmacology; 71; 8; 8-2015; 1011-10190031-6970CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/https://link.springer.com/article/10.1007/s00228-015-1881-4info:eu-repo/semantics/altIdentifier/doi/10.1007/s00228-015-1881-4info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-29T09:36:18Zoai:ri.conicet.gov.ar:11336/38806instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-29 09:36:19.005CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Trends in inpatient antiparkinson drug use in the USA, 2001-2012
title Trends in inpatient antiparkinson drug use in the USA, 2001-2012
spellingShingle Trends in inpatient antiparkinson drug use in the USA, 2001-2012
Crispo, James
Cohort Study
Drug Utilization
Medical Records
Parkinson'S Disease
Pharmacoepidemiology
title_short Trends in inpatient antiparkinson drug use in the USA, 2001-2012
title_full Trends in inpatient antiparkinson drug use in the USA, 2001-2012
title_fullStr Trends in inpatient antiparkinson drug use in the USA, 2001-2012
title_full_unstemmed Trends in inpatient antiparkinson drug use in the USA, 2001-2012
title_sort Trends in inpatient antiparkinson drug use in the USA, 2001-2012
dc.creator.none.fl_str_mv Crispo, James
Fortin, Yannick
Thibault, Dylan P.
Emons, Matthew
Bjerre, Lise M.
Kohen, Dafna E.
Pérez Lloret, Santiago
Mattison, Donald
Willis, Allison W.
Krewski, Daniel
author Crispo, James
author_facet Crispo, James
Fortin, Yannick
Thibault, Dylan P.
Emons, Matthew
Bjerre, Lise M.
Kohen, Dafna E.
Pérez Lloret, Santiago
Mattison, Donald
Willis, Allison W.
Krewski, Daniel
author_role author
author2 Fortin, Yannick
Thibault, Dylan P.
Emons, Matthew
Bjerre, Lise M.
Kohen, Dafna E.
Pérez Lloret, Santiago
Mattison, Donald
Willis, Allison W.
Krewski, Daniel
author2_role author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Cohort Study
Drug Utilization
Medical Records
Parkinson'S Disease
Pharmacoepidemiology
topic Cohort Study
Drug Utilization
Medical Records
Parkinson'S Disease
Pharmacoepidemiology
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.2
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv Purpose: Although therapeutic options and clinical guidelines for Parkinson's disease (PD) have changed significantly in the past 15 years, prescribing trends in the USA remain unknown. The purpose of this population-based cohort study was to examine patterns of inpatient antiparkinson drug use between January 2001 and December 2012 in relation to clinical guideline publication, drug introduction/withdrawal, and emerging safety concerns. Methods: A total of 16,785 inpatients receiving pharmacological treatment for PD were identified in the Cerner Health Facts database. Our primary outcome was standardized (age, sex, race, and census region) annual prevalence of antiparkinson drug use. We also examined antiparkinson medication trends and polypharmacy by age and sex. Results: The most frequently prescribed antiparkinson drugs between 2001 and 2012 were levodopa (85 %) and dopamine agonists (28 %). Dopamine agonist use began declining in 2007, from 34 to 27 % in 2012. The decline followed publication of the American Academy of Neurology's practice parameter refuting levodopa toxicity, pergolide withdrawal, and pramipexole label revisions. Despite safety concerns for cognitive impairment and falls, individuals = 80 years of age demonstrated stable rates of dopamine agonist use from 2001 to 2012. Polypharmacy was most common in younger patients. Conclusions: Dopamine agonist use declined from 2007 to 2012, suggesting that increased awareness of safety issues and practice guidelines influenced prescribing. These events appear to have minimally influenced treatment provided to older PD patients. Antiparkinson prescribing trends indicate that safety and best practice information may be communicated effectively.
Fil: Crispo, James. University of Ottawa; Canadá. University of Pennsylvania; Estados Unidos
Fil: Fortin, Yannick. University of Ottawa; Canadá
Fil: Thibault, Dylan P.. University of Pennsylvania; Estados Unidos
Fil: Emons, Matthew. Cerner Corporation; Estados Unidos
Fil: Bjerre, Lise M.. University of Ottawa; Canadá. Bruyère Research Institute; Canadá
Fil: Kohen, Dafna E.. University of Ottawa; Canadá
Fil: Pérez Lloret, Santiago. Pontificia Universidad Católica Argentina "Santa María de los Buenos Aires"; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Mattison, Donald. Risk Sciences International; Canadá. University of Ottawa; Canadá
Fil: Willis, Allison W.. University of Pennsylvania; Estados Unidos
Fil: Krewski, Daniel. University of Ottawa; Canadá
description Purpose: Although therapeutic options and clinical guidelines for Parkinson's disease (PD) have changed significantly in the past 15 years, prescribing trends in the USA remain unknown. The purpose of this population-based cohort study was to examine patterns of inpatient antiparkinson drug use between January 2001 and December 2012 in relation to clinical guideline publication, drug introduction/withdrawal, and emerging safety concerns. Methods: A total of 16,785 inpatients receiving pharmacological treatment for PD were identified in the Cerner Health Facts database. Our primary outcome was standardized (age, sex, race, and census region) annual prevalence of antiparkinson drug use. We also examined antiparkinson medication trends and polypharmacy by age and sex. Results: The most frequently prescribed antiparkinson drugs between 2001 and 2012 were levodopa (85 %) and dopamine agonists (28 %). Dopamine agonist use began declining in 2007, from 34 to 27 % in 2012. The decline followed publication of the American Academy of Neurology's practice parameter refuting levodopa toxicity, pergolide withdrawal, and pramipexole label revisions. Despite safety concerns for cognitive impairment and falls, individuals = 80 years of age demonstrated stable rates of dopamine agonist use from 2001 to 2012. Polypharmacy was most common in younger patients. Conclusions: Dopamine agonist use declined from 2007 to 2012, suggesting that increased awareness of safety issues and practice guidelines influenced prescribing. These events appear to have minimally influenced treatment provided to older PD patients. Antiparkinson prescribing trends indicate that safety and best practice information may be communicated effectively.
publishDate 2015
dc.date.none.fl_str_mv 2015-08
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/38806
Crispo, James; Fortin, Yannick; Thibault, Dylan P.; Emons, Matthew; Bjerre, Lise M.; et al.; Trends in inpatient antiparkinson drug use in the USA, 2001-2012; Springer; European Journal Of Clinical Pharmacology; 71; 8; 8-2015; 1011-1019
0031-6970
CONICET Digital
CONICET
url http://hdl.handle.net/11336/38806
identifier_str_mv Crispo, James; Fortin, Yannick; Thibault, Dylan P.; Emons, Matthew; Bjerre, Lise M.; et al.; Trends in inpatient antiparkinson drug use in the USA, 2001-2012; Springer; European Journal Of Clinical Pharmacology; 71; 8; 8-2015; 1011-1019
0031-6970
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/url/https://link.springer.com/article/10.1007/s00228-015-1881-4
info:eu-repo/semantics/altIdentifier/doi/10.1007/s00228-015-1881-4
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Springer
publisher.none.fl_str_mv Springer
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1844613138176016384
score 13.070432

Publicaciones similares